Brief: Maia Biotech Announces Positive Preliminary Efficacy Data For Ongoing Thio-101 Phase 2 Trial

Maia Biotechnology

24/10/2023 14:11

Oct 24 (Reuters) - Maia Biotechnology Inc  MAIA.A :
    * MAIA BIOTECHNOLOGY ANNOUNCES 100% DISEASE CONTROL IN
SECOND-LINE
NON-SMALL CELL LUNG CANCER DEMONSTRATING IMPRESSIVE POSITIVE
PRELIMINARY EFFICACY DATA FOR ONGOING THIO-101 PHASE 2 TRIAL
    * MAIA BIOTECHNOLOGY - UNPRECEDENTED DISEASE CONTROL RATE OF
100%
IN SECOND-LINE OF TREATMENT FAR SURPASSES STANDARD OF CARE (SOC)
DCR OF 53-64%
    * MAIA BIOTECHNOLOGY - DCRS ACROSS ALL DOSE LEVELS MET
PRE-DETERMINED STATISTICAL REQUIREMENTS EARLIER THAN EXPECTED TO
PROCEED TO NEXT STAGE OF TRIAL

Source text for Eikon:  ID:nBw8php55a 
Further company coverage:  MAIA.A 

 ((Reuters.Briefs@thomsonreuters.com))